227 related articles for article (PubMed ID: 24145880)
21. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
Colombo S; Buclin T; Cavassini M; Décosterd LA; Telenti A; Biollaz J; Csajka C
Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
[TBL] [Abstract][Full Text] [Related]
23. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
Fukushima K; Haraya K; Terasaka S; Ito Y; Sugioka N; Takada K
Biol Pharm Bull; 2008 Jun; 31(6):1209-14. PubMed ID: 18520056
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
Rhame FS; Rawlins SL; Petruschke RA; Erb TA; Winchell GA; Wilson HM; Edelman JM; Abramson MA
Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
[TBL] [Abstract][Full Text] [Related]
25. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
[TBL] [Abstract][Full Text] [Related]
26. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.
Burger DM; Huisman A; Van Ewijk N; Neisingh H; Van Uden P; Rongen GA; Koopmans P; Bertz RJ
Clin Pharmacol Ther; 2008 Dec; 84(6):698-703. PubMed ID: 18528434
[TBL] [Abstract][Full Text] [Related]
27. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
28. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
Feldt T; Oette M; Kroidl A; Göbels K; Leidel R; Sagir A; Kuschak D; Häussinger D
Eur J Med Res; 2005 Jan; 10(1):7-10. PubMed ID: 15737947
[TBL] [Abstract][Full Text] [Related]
29. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
30. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
[TBL] [Abstract][Full Text] [Related]
32. Optimizing treatment in HIV/HCV coinfection.
Puoti M; Rossotti R; Travi G; Panzeri C; Morreale M; Chiari E; Cocca G; Orso M; Moioli MC
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S355-62. PubMed ID: 24091116
[TBL] [Abstract][Full Text] [Related]
33. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
34. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
35. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Baril J; Conway B; Giguère P; Ferko N; Hollmann S; Angel JB
HIV Med; 2014 May; 15(5):301-10. PubMed ID: 24314017
[TBL] [Abstract][Full Text] [Related]
37. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
Else LJ; Jackson V; Brennan M; Back DJ; Khoo SH; Coulter-Smith S; Lambert JS
HIV Med; 2014 Nov; 15(10):604-10. PubMed ID: 24825070
[TBL] [Abstract][Full Text] [Related]
40. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
